Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine versus placebo in children and adolescents with ADHD and comorbid oppositional defiant disorder
2006-001471-37Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of atomoxetine in attention deficit hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Improvement in oppositional defiant disorder symptoms. Started Aug 2006; status: completed.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)oppositional defiant disorder (ODD)
Beyond the preview
Go deeper on 2006-001471-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001471-37.